Regen BioPharma Inc. Files 8-K with Material Agreements
Ticker: RGBPP · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1589150
| Field | Detail |
|---|---|
| Company | Regen Biopharma INC (RGBPP) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Regen BioPharma filed an 8-K on 7/28/25 detailing material agreements and equity sales.
AI Summary
On July 28, 2025, Regen BioPharma Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on August 1, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions, including definitive agreements and equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks that require careful monitoring.
Key Players & Entities
- Regen BioPharma Inc. (company) — Issuer
- July 28, 2025 (date) — Date of earliest event reported
- August 1, 2025 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- 4700 Spring Street, St 304, La Mesa, California 91942 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Regen BioPharma Inc. enter into?
The filing states that Regen BioPharma Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 28, 2025.
What is Regen BioPharma Inc.'s principal executive office address?
Regen BioPharma Inc.'s principal executive office is located at 4700 Spring Street, St 304, La Mesa, California 91942.
What is Regen BioPharma Inc.'s telephone number?
Regen BioPharma Inc.'s telephone number is (619) 722-5505.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the entry into a Material Definitive Agreement, unregistered sales of equity securities, and financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding Regen BioPharma Inc (RGBPP).